1998 Fiscal Year Final Research Report Summary
Elevation of plasma TGF-b in cancer patients and study on its molecular mechanism.
| Project/Area Number |
09557052
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
KAWATA Sumio Osaka University Medical School, Associate professor, 医学部, 助教授 (90183285)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
木曽 真一 大阪大学, 医学部・附属病院, 医員
FUKUDA Kazuto Osaka University Hospital, Medical Staff, 医学部・附属病院, 医員
TAMURA Shinji Osaka University Medical School, Associate professor, 医学部, 助手 (30243223)
KISO Shinich Osaka University Hospital, Medical Staff
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Keywords | TGF-b / plasma TGF-b1 / TGF-b receptor / anti-TGF-b therapy |
|---|
| Research Abstract |
We have reported that TGF-bl is produced by human hepatocellular carcinoma and colon cancer and that plasma TGF-bl concentration is elevated in patients with these cancers. The circulated TGF-b1 contributed to reduced anti-tumor immunity and enhanced vascularity in the timors.
Our hypothesis is that the circulating TGF-bl may contribute to prognosis of the patients. We divided 70 patients with hepatocellular carcinoma into a group with high concentration of plasma TGF-IA (more than 8.7 ng/ml) and a group with low concentration (below 8.7). The survival time was short in the group with high concenteration. This result was confirmed in each tumor stage. Cox proportional-hazard regression analysis showed that plasma TGF-bl concentration is a risk factor contributing for the prognosis.
We also are studying on anti-tumor effect of recombinant soluble form TGF-b receptor type II against human hepatoma transplanted in nude mice. These experiments may lead to anti-TGF-b therapy in human cancer patients.
|
